Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old.

Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor ... (CSF1R), release signals that bring other inflammation-causing cells to the tumor site.

A 37-year-old woman says that if she hadn’t doggedly called doctors’ offices and insisted to be seen ASAP, she’d still have a rare, massive tumor growing inside her, eating away at her bones.

CHICAGO -- An oral investigational agent effectively shrank tenosynovial giant cell tumors (TGCTs) while demonstrating functional and symptomatic benefits for patients, the phase III MOTION trial ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

US FDA grants full approval of Deciphera’s Romvimza™ (vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT). News release. Deciphera Pharmaceuticals. February 14 ...

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...

Cassier PA, Italiano A, Gomez-Roca C, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

Treatment with emactuzumab has received fast track designation from the United States Food and Drug Administration (FDA) for patients with tenosynovial giant cell tumor (TGCT) who are not amenable to ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

CHICAGO -- An oral investigational agent effectively shrank tenosynovial giant cell tumors (TGCTs) while demonstrating functional and symptomatic benefits for patients, the phase III MOTION trial ...